基本信息
views: 241
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
DESCRIPTION OF RESEARCH:
Dr. Teh’s research focuses on the treatment of genito-urinary malignancies and unlocking the myth of radio-resistance in cancers especially renal cell carcinoma. Other research interests include Intensity modulated radiation therapy (IMRT) for prostate cancer, head and neck cancer, central nervous system tumor, pediatric cancer and breast cancer, stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), stereotactic radiation therapy (SRT) and image-guided radiation therapy (IGRT), brachytherapy for prostate cancer, breast cancer and endobronchial tumors, SRS and SBRT for primary and metastatic renal cell carcinoma as well as hepatocellular carcinoma, the role of combined radiotherapy and gene therapy for cancers including prostate cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer and head and neck cancer, combining targeted therapy (AKT-inhibitor, mTOR inhibitor, tyrosine kinase inhibitor) with radiotherapy for cancer treatment, and combining oncolytic virus with radiotherapy in overcoming radio-resistant tumors in oncology.
AREAS OF EXPERTISE:
Cancer stem cells Radio-resistance Prostate Movement study Post-prostatectomy IMRT Gene expression profiling in cancer Proteomics in oncology
Dr. Teh’s research focuses on the treatment of genito-urinary malignancies and unlocking the myth of radio-resistance in cancers especially renal cell carcinoma. Other research interests include Intensity modulated radiation therapy (IMRT) for prostate cancer, head and neck cancer, central nervous system tumor, pediatric cancer and breast cancer, stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), stereotactic radiation therapy (SRT) and image-guided radiation therapy (IGRT), brachytherapy for prostate cancer, breast cancer and endobronchial tumors, SRS and SBRT for primary and metastatic renal cell carcinoma as well as hepatocellular carcinoma, the role of combined radiotherapy and gene therapy for cancers including prostate cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer and head and neck cancer, combining targeted therapy (AKT-inhibitor, mTOR inhibitor, tyrosine kinase inhibitor) with radiotherapy for cancer treatment, and combining oncolytic virus with radiotherapy in overcoming radio-resistant tumors in oncology.
AREAS OF EXPERTISE:
Cancer stem cells Radio-resistance Prostate Movement study Post-prostatectomy IMRT Gene expression profiling in cancer Proteomics in oncology
Research Interests
Papers共 668 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Brachytherapy (2024)
Vivian S Tan, Rohann J M Correa, Andrew Warner,Muhammad Ali, Alexander Muacevic, Lee Ponsky, Rodney J Ellis, Simon S Lo,Hiroshi Onishi, Anand Swaminath,Young Suk Kwon, Scott C Morgan,
European urology oncology (2024)
Andrew B. Barbour,Rituraj Upadhyay, August C. Anderson,Tugce Kutuk,Ritesh Kumar,Shang-Jui Wang, Sarah P. Psutka,Fatemeh Fekrmandi, Karin A. Skalina, Anna M.E. Bruynzeel, Rohann J.M. Correa,Alan Dal Pra,
CURRENT ONCOLOGYno. 3 (2024): 1588-1599
Chinese clinical oncologyno. 3 (2023): 29-29
crossref(2023)
Ximing J. Yang,Min-Han Tan,Hyung L. Kim,Jonathon A. Ditlev, Mark W. Betten, Carolina E. Png,Eric J. Kort,Kunihiko Futami,Kyle A. Furge,Masayuki Takahashi,Hiro-omi Kanayama,Puay Hoon Tan,
crossref(2023)
CANCERSno. 14 (2023): 3672-3672
Chinese clinical oncologyno. 3 (2023): 26
CANCER RESEARCHno. 7 (2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn